Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

The broad range of clinical activity of thymic carcinomas makes the likelihood of detecting
efficacy of a single agent such as premetrexed a reasonable objective since these
malignancies are relatively slow growing and exhibit a broad range of chemosensitivity to
antineoplastic agents.

Inclusion Criteria:

- Histologically confirmed invasive, recurrent or metastatic thymoma or thymic
carcinoma not amenable to potentially curative therapy by surgery. Original biopsy of
tumor is sufficient for diagnoses unless otherwise clinically indicated.

- Patients must have measurable disease with at least one bidimensional measurable
lesion. Any scans or x-rays used to document measurable disease must be obtained with
6 weeks prior to registration.

- Patients may have had prior chemotherapy for metastatic disease

- Adequate organ function as defined by: bili /=45;
hematologic-granulocytes >/=1500 & plt >/=100K.

- Patients who are receiving a stable dose of corticosteroids for myasthenia gravis are
eligible.

- ECOG performance status of 0 or 1

Exclusion Criteria:

- Acute intercurrent infection or complications

- pregnancy or lactating patients

- Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a
5-day period (8-day period for long-acting agents.

- Presence of clinically relevant third-space fluid collections that cannot be
controlled by a procedure